Based on the linear regression slopes (Table 2), each 10% reduction in body weight with semaglutide was associated with a 6.4-point (95% confidence interval (CI): 4.1, 8.8) increase in KCCQ-CSS, a 14.4-m (95% CI: 5.5, 23.3) increase in 6MWD and a 28% (95% CI: 16, 37) decrease in CRP, after adjusting for baseline age, sex, body weight, endpoint value, NYHA class, coronary artery disease, atrial fibrillation, CRP (log-transformed) and NTproBNP (log-transformed). This evidence concerns the gene NPPB and coronary artery disorder.